Literature DB >> 12057021

Malarone treatment failure and in vitro confirmation of resistance of Plasmodium falciparum isolate from Lagos, Nigeria.

Quinton L Fivelman1, Geoffrey A Butcher, Ipemida S Adagu, David C Warhurst, Geoffrey Pasvol.   

Abstract

We report the first in vitro and genetic confirmation of Malarone (GlaxoSmithKline; atovaquone and proguanil hydrochloride) resistance in Plasmodium falciparum acquired in Africa. On presenting with malaria two weeks after returning from a 4-week visit to Lagos, Nigeria without prophylaxis, a male patient was given a standard 3-day treatment course of Malarone. Twenty-eight days later the parasitaemia recrudesced. Parasites were cultured from the blood and the isolate (NGATV01) was shown to be resistant to atovaquone and the antifolate pyrimethamine. The cytochrome b gene of isolate NGATV01 showed a single mutation, Tyr268Asn which has not been seen previously.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12057021      PMCID： PMC111499          DOI： 10.1186/1475-2875-1-1

Source DB:  PubMed          Journal:  Malar J        ISSN： 1475-2875            Impact factor:   2.979


  17 in total

1.  Sustainability, affordability, and equity of corporate drug donations: the case of Malarone.

Authors:  R Shretta; R Brugha; A Robb; R W Snow
Journal:  Lancet       Date:  2000-05-13       Impact factor: 79.321

2.  Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand.

Authors:  S Looareesuwan; C Viravan; H K Webster; D E Kyle; D B Hutchinson; C J Canfield
Journal:  Am J Trop Med Hyg       Date:  1996-01       Impact factor: 2.345

3.  In vitro activity of pyrimethamine, cycloguanil, and other antimalarial drugs against African isolates and clones of Plasmodium falciparum.

Authors:  L K Basco; O Ramiliarisoa; J Le Bras
Journal:  Am J Trop Med Hyg       Date:  1994-02       Impact factor: 2.345

4.  Resistance mutations reveal the atovaquone-binding domain of cytochrome b in malaria parasites.

Authors:  I K Srivastava; J M Morrisey; E Darrouzet; F Daldal; A B Vaidya
Journal:  Mol Microbiol       Date:  1999-08       Impact factor: 3.501

5.  Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travellers: a randomised, double-blind study. Malarone International Study Team.

Authors:  B Høgh; P D Clarke; D Camus; H D Nothdurft; D Overbosch; M Günther; I Joubert; K C Kain; D Shaw; N S Roskell; J D Chulay
Journal:  Lancet       Date:  2000-12-02       Impact factor: 79.321

6.  Atovaquone and proguani hydrochloride compared with chloroquine or pyrimethamine/sulfodaxine for treatment of acute Plasmodium falciparum malaria in Peru.

Authors:  A Llanos-Cuentas; P Campos; M Clendenes; C J Canfield; D B Hutchinson
Journal:  Braz J Infect Dis       Date:  2001-04       Impact factor: 1.949

7.  Atovaquone resistance in malaria parasites.

Authors:  Akhil B. Vaidya; Michael W. Mather
Journal:  Drug Resist Updat       Date:  2000-10       Impact factor: 18.500

8.  Inhibition of the mosquito transmission of Plasmodium berghei by Malarone (atovaquone-proguanil).

Authors:  G A Butcher; J Mendoza; R E Sinden
Journal:  Ann Trop Med Parasitol       Date:  2000-07

Review 9.  Malarone (atovaquone and proguanil hydrochloride): a review of its clinical development for treatment of malaria. Malarone Clinical Trials Study Group.

Authors:  S Looareesuwan; J D Chulay; C J Canfield; D B Hutchinson
Journal:  Am J Trop Med Hyg       Date:  1999-04       Impact factor: 2.345

10.  Atovaquone, a broad spectrum antiparasitic drug, collapses mitochondrial membrane potential in a malarial parasite.

Authors:  I K Srivastava; H Rottenberg; A B Vaidya
Journal:  J Biol Chem       Date:  1997-02-14       Impact factor: 5.157
View more
  56 in total

1.  Malaria antifolate resistance with contrasting Plasmodium falciparum dihydrofolate reductase (DHFR) polymorphisms in humans and Anopheles mosquitoes.

Authors:  Sungano Mharakurwa; Taida Kumwenda; Mtawa A P Mkulama; Mulenga Musapa; Sandra Chishimba; Clive J Shiff; David J Sullivan; Philip E Thuma; Kun Liu; Peter Agre
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-07       Impact factor: 11.205

2.  Modified fixed-ratio isobologram method for studying in vitro interactions between atovaquone and proguanil or dihydroartemisinin against drug-resistant strains of Plasmodium falciparum.

Authors:  Quinton L Fivelman; Ipemida S Adagu; David C Warhurst
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

3.  First case of emergence of atovaquone resistance in Plasmodium falciparum during second-line atovaquone-proguanil treatment in South America.

Authors:  Eric Legrand; Magalie Demar; Béatrice Volney; Marie-Thérèse Ekala; Marc Quinternet; Christiane Bouchier; Thierry Fandeur; Christophe Rogier; Bernard Carme; Odile Mercereau Puijalon; Philippe Esterre
Journal:  Antimicrob Agents Chemother       Date:  2007-04-16       Impact factor: 5.191

4.  Evidence of Plasmodium falciparum malaria resistant to atovaquone and proguanil hydrochloride: case reports.

Authors:  Anna Färnert; Johan Lindberg; Pedro Gil; Göte Swedberg; Yngve Berqvist; Mita M Thapar; Niklas Lindegårdh; Sándor Berezcky; A Björkman
Journal:  BMJ       Date:  2003-03-22

5.  First case of emergence of atovaquone-proguanil resistance in Plasmodium falciparum during treatment in a traveler in Comoros.

Authors:  Helene Savini; Hervé Bogreau; Lionel Bertaux; Housem Bouchiba; Philippe Kraemer; Daniel Parzy; Eric Garnotel; Christophe Rogier; Fabrice Simon; Bruno Pradines
Journal:  Antimicrob Agents Chemother       Date:  2008-04-14       Impact factor: 5.191

6.  [Malaria--current diagnosis and therapy].

Authors:  Isabel Barreto Miranda; Thomas Löscher
Journal:  Med Klin (Munich)       Date:  2009-07-15

7.  Molecular characterization of the cytochrome b gene and in vitro atovaquone susceptibility of Plasmodium falciparum isolates from Kenya.

Authors:  Luicer A Ingasia; Hoseah M Akala; Mabel O Imbuga; Benjamin H Opot; Fredrick L Eyase; Jacob D Johnson; Wallace D Bulimo; Edwin Kamau
Journal:  Antimicrob Agents Chemother       Date:  2015-01-12       Impact factor: 5.191

8.  Plasmodium chabaudi chabaudi malaria parasites can develop stable resistance to atovaquone with a mutation in the cytochrome b gene.

Authors:  Ana Afonso; Zoraima Neto; Helena Castro; Dinora Lopes; Ana C Alves; Ana M Tomás; Virgílio D Rosário
Journal:  Malar J       Date:  2010-05-21       Impact factor: 2.979

9.  Genome sequencing sheds light on emerging drug resistance in malaria parasites.

Authors:  Daniel E Neafsey
Journal:  Nat Genet       Date:  2013-06       Impact factor: 38.330

10.  Mutations in the Plasmodium falciparum cytochrome b gene are associated with delayed parasite recrudescence in malaria patients treated with atovaquone-proguanil.

Authors:  Colin J Sutherland; Matt Laundy; Nicholas Price; Martina Burke; Quinton L Fivelman; Geoffrey Pasvol; John L Klein; Peter L Chiodini
Journal:  Malar J       Date:  2008-11-20       Impact factor: 2.979
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.